中文摘要：

瞄准：评估一个混合 bioartificial 肝(HBAL ) 的功效和安全在尖锐的肝的处理的系统失败。方法：有尖锐的肝失败的犬的模型与 D-galactosamine 的静脉内的管理被介绍。动物被划分成：HBAL 处理组(n = 8 ) ，在哪个 canines 接受了 HBAL 的一个 3-h 处理；bioartificial 肝(BAL ) 处理组(n = 8 ) ，在哪个 canines 接受了 BAL 的一个 3-h 处理；non-bioartificial 肝(NBAL ) 处理组(n = 8 ) ，在哪个 canines 接受了 NBAL 的一个 3-h 处理；控制组(n = 8 ) ，在哪个 canines 没接受另外的处理。生物化学的参数和幸存时间是坚定的。xenoantibodies，猪的内长的 retrovirus (PERV ) 的 RNA 和反向的 transcriptase (RT ) 的层次在血浆的活动被检测。结果：生物化学的参数显著地在所有处理组被减少。在 HBAL 组的 TBIL 水平在另外的组是比那低的(2.19 汰祡吗？

英文摘要：

AIM： To evaluate the efficacy and safety of a hybrid bioartificial liver （HBAL） system in the treatment of acute liver failure. METHODS： Canine models with acute liver failure were introduced with intravenous administration of D-galactosamine. The animals were divided into： the HBAL treatment group （n = 8）, in which the canines received a 3-h treatment of HBAL; the bioartificial liver （BAL） treatment group （n = 8）, in which the canines received a 3-h treatment of BAL; the non-bioartificial liver （NBAL） treatment group （n = 8）, in which the canines received a 3-h treatment of NBAL; the control group （n = 8）, in which the canines received no additional treatment. Biochemical parameters and survival time were determined. Levels of xenoantibodies, RNA of porcine endogenous retrovirus （PERV） and reverse transcriptase （RT） activity in the plasma were detected. RESULTS： Biochemical parameters were significantly decreased in all treatment groups. The TBIL level in the HBAL group was lower than that in other groups （2.19 ± 0.55 mmol/L vs 24.2 ± 6.45 mmol/L, 12.47 ± 3.62 mmol/L, 3.77 ± 1.83 mmol/L, P 0.05）. The prothrombin time （PT） in the BAL and HBAL groups was significantly shorter than the NBAL and control groups （18.47 ± 4.41 s, 15.5 ± 1.56 s vs 28.67 ± 5.71 s, 21.71 ± 3.4 s, P 0.05）, and the PT in the HBAL group was shortest of all the groups. The albumin in the BAL and HBAL groups significantly increased and a significantly higher level was observed in the HBAL group compared with the BAL group （27.7 ± 1.7 g/L vs 25.24 ± 1.93 g/L）. In the HBAL group, the ammonia levels significantly decreased from 54.37 ± 6.86 to 37.75 ± 6.09 after treatment （P 0.05）; there were significant difference in ammonia levels between other the groups （P 0.05）. The levels of antibodies were similar before and after treatment. The PERV RNA and the RT activity in the canine plasma were all negative. CONCLUSION： The HBAL showed great efficiency and safety in the